Clinical Trial Update: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on guselkumab for moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2017-11-06